Improved Treatment of Colorectal Cancer with CF10 Diversity Supplement

使用 CF10 多样性补充剂改善结直肠癌的治疗

基本信息

批准号：
10543218
负责人：
William H Gmeiner
金额：
$ 10.45万
依托单位：
DEEP CREEK PHARMA, LLC
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-02-01 至 2022-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10543218
关键词：
Address Administrative Supplement Biochemical Businesses Cancer Model Cell Line Chemosensitization Clinical Clinical Research Colonic Neoplasms Colorectal Cancer Complement Development Development Plans Entrepreneurship Fluorouracil Fostering Funding Generations Goals Growth Laboratories Leucovorin MC38 Malignant neoplasm of liver Measures Mentors Minority Modeling Molecular Pharmaceutical Preparations Pharmacology Phase Physiology Polyethylene Glycols Polymers Pre-Clinical Model Preclinical Drug Development Rattus Regimen Research Personnel Resistance Schedule Small Business Technology Transfer Research Technical Expertise Technology Toxic effect Training Translational Research Translations Writing antitumor agent cancer cell career career development career networking clinical candidate clinical development colorectal cancer treatment fluoropyrimidine forest improved in vivo medical schools meetings metastatic colorectal mortality non-Native novel nucleoside analog pre-doctoral programs resistance factors skills tumor

项目摘要

Project Summary for Supplement to CA254834 This minority administrative supplement to CA254834 requests funds for training Charles Chidi Okechukwu in the translational objectives of the Phase 1 STTR project and developing new business development and entrepreneurial skills fir the candidate that will support company growth. The funded Phase 1 STTR project (CA254834) focuses on demonstrating that a novel FP polymer, CF10, displays improved activity in pre-clinical models of metastatic colorectal cancer (mCRC). Currently funded Aims are: i) Demonstrate CF10 inhibits CRC metastatic progression in an orthotopic colon tumor model; ad ii) Demonstrate improved anti-metastatic activity for CF10 in a rat syngeneic CRC liver met model. With supplement funding, Charles will investigate if CF10 will be effective in treating CRC with acquired resistance to 5-FU and will be potentiated in combination with leucovorin (LV; folinic acid), which complements ongoing studies. The supplemental Aims are: S1) Demonstrate improved anti-metastatic activity for CF10 in 5-FU-resistant orthotopic CRC models; and S2) Evaluate Leucovorin potentiation of CF10 in 5-FU-resistant orthotopic CRC models. The mentoring plan for Charles will include training in technical skills related to pre-clinical drug development, translational research, and entrepreneurship. Training will include interfacing with researchers, clinical experts, and with business development experts. Charles will also receive mentoring in writing skills, including business plan development, and presentation skills, including presentation to investors. Training will enhance the long-term career opportunities of the applicant, including development of a professional network, and advance the goals of the company in commercializing CF10 technology.

CA254834补充的项目摘要 CA254834的少数族裔行政补充要求培训资金，以培训Charles Chidi okechukwu 第1阶段STTR项目的转化目标以及开发新的业务发展和企业家技能将支持公司增长的候选人。资助的第一阶段STTR项目（CA254834）专注于证明一种新型的FP聚合物CF10显示出改善的临床活动的活性转移性结直肠癌（MCRC）的模型。目前资助的目标是：i）演示CF10抑制CRC 原位结肠肿瘤模型中的转移进展；广告ii）证明了改善的抗转移活性对于大鼠同性CRC肝MET模型中的CF10。通过补充资金，查尔斯将调查CF10是否会有效地治疗获得5-FU的CRC，并将与白细胞素（LV；叶酸），它补充正在进行的研究。补充目的是：S1）证明在5-FU的原位CRC模型中，CF10改善了CF10的抗转移活性；和S2）评估 CF10在5-FU的原位CRC模型中的leucovorin增强。查尔斯的指导计划将包括与临床前药物开发，翻译研究以及企业家精神。培训将包括与研究人员，临床专家的接口以及业务发展专家。查尔斯还将获得写作技巧的指导，包括商业计划的制定，和演讲技巧，包括向投资者展示。培训将增强长期职业申请人的机会，包括开发专业网络，并促进目标的目标公司商业化CF10技术。